Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3.
Periodontitis is an inflammatory disease of the supporting structures of the teeth caused by, among other pathogens, Prevotella intermedia. Many strains of P. intermedia are resistant to killing by the human complement system, which is present at up to 70% of serum concentration in gingival crevicular fluid. Incubation of human serum with recombinant cysteine protease of P. intermedia (interpain A) resulted in a drastic decrease in bactericidal activity of the serum. Furthermore, a clinical strain 59 expressing interpain A was more serum-resistant than another clinical strain 57, which did not express interpain A, as determined by Western blotting. Moreover, in the presence of the cysteine protease inhibitor E64, the killing of strain 59 by human serum was enhanced. Importantly, we found that the majority of P. intermedia strains isolated from chronic and aggressive periodontitis carry and express the interpain A gene. The protective effect of interpain A against serum bactericidal activity was found to be attributable to its ability to inhibit all three complement pathways through the efficient degradation of the alpha-chain of C3 -- the major complement factor common to all three pathways. P. intermedia has been known to co-aggregate with P. gingivalis, which produce gingipains to efficiently degrade complement factors. Here, interpain A was found to have a synergistic effect with gingipains on complement degradation. In addition, interpain A was able to activate the C1 complex in serum, causing deposition of C1q on inert and bacterial surfaces, which may be important at initial stages of infection when local inflammatory reaction may be beneficial for a pathogen. Taken together, the newly characterized interpain A proteinase appears to be an important virulence factor of P. intermedia.
Potempa
Michal
M
Lund University, Department of Laboratory Medicine, Section of Medical Protein Chemistry, University Hospital Malmö, Malmö, Sweden.
Potempa
Jan
J
Kantyka
Tomasz
T
Nguyen
Ky-Anh
KA
Wawrzonek
Katarzyna
K
Manandhar
Surya P
SP
Popadiak
Katarzyna
K
Riesbeck
Kristian
K
Eick
Sigrun
S
Blom
Anna M
AM
D018829:Adhesins, Bacterial / Q000502:physiology*; D001426:Bacterial Proteins / Q000502:physiology*; D001770:Blood Bactericidal Activity / Q000276:immunology; D003167:Complement Activation; D015922:Complement C1q / Q000276:immunology; D003176:Complement C3 / Q000276:immunology*; D003181:Complement C4 / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology; D003546:Cysteine Endopeptidases / Q000502:physiology*; D015853:Cysteine Proteinase Inhibitors / Q000378:metabolism; D004357:Drug Synergism; D005881:Gingiva / Q000378:metabolism; D006801:Humans; D018713:Prevotella intermedia / Q000201:enzymology*
D018829:Adhesins, Bacterial; D001426:Bacterial Proteins; D003176:Complement C3; D003181:Complement C4; D015853:Cysteine Proteinase Inhibitors; D015922:Complement C1q; D003165:Complement System Proteins; D003546:Cysteine Endopeptidases